Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Up 5.52%
As of Thursday, July 30, Arcus Biosciences, Inc.’s RCUS share price has surged by 5.52%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Commentary & Analysis
Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Up 6.74%
As of Monday, July 20, Arcus Biosciences, Inc.’s RCUS share price has surged by 6.74%, which has investors questioning if this is right time to sell.Michael Rose
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or Arcus Biosciences, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Why Arcus Biosciences, Inc.’s (RCUS) Stock Is Up 6.70%
As of Thursday, June 25, Arcus Biosciences, Inc.’s RCUS share price has surged by 6.70%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Which Is a Better Investment, Nurix Therapeutics, Inc. or Arcus Biosciences, Inc. Stock?
Learn more about whether Nurix Therapeutics, Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Financial Summary
| Share Statistics | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,545.5 | $252.6 | 62% |
|
| Shares Out (Mil) | 125.4 | 52.3 | 67% |
|
| Institutional Ownership | 95.1% | 92.1% | 67% |
|
| Float (Mil) | 89.0 | 40.2 | 59% |
|
| Beta | 0.84 | 0.95 | 50% |
|
| Avg Daily Volume (000s) | 1,149 | 455 | 73% |
|
| Price Change (52-week) |
198.9% | 52.9% | 97% |
|
| Growth | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 25.9% | 13.6% | 87% |
|
| Net Income (5yr) | (23.5%) | (9.9%) | 17% |
|
| EPS (5yr) | (7.9%) | 16.0% | 23 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (20.6%) | (15.6%) | 32% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.814) | ($3.483) | ($3.103) | |
| Month Ago EPS | ($0.814) | ($3.483) | ($3.103) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.833) | ($3.645) | ($3.530) | |
| Year/Year Chg | (20.3%) | 6.0% | (20.2%) | |
| Financials | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $236 | $38 | 34% |
|
| Net Income (TTM) (Mil) | ($369) | ($43) | 4% |
|
| EPS (TTM) | ($3.233) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($488) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $9 | $5 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $219 | $5 | 51% |
|
| Enterprise Value (Q1) (Mil) | $2,900 | $180 | 54% |
|
| Valuation | RCUS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.74 | 2.56 | 84% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RCUS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (121.6%) | 63.8% | 2% |
|
| Net Margin | (156.4%) | (67.3%) | 6% |
|
| ROA | (34.3%) | (49.8%) | 16% |
|
| ROE | (70.0%) | (55.5%) | 12% |
|
| Liabilities to Assets | 47.4% | 30.3% | 39% |
|
| F-Score | 2 | 3 | 7% |
|
Arcus Biosciences, Inc. did not pass any screens on 7/31/2026.
